WILMINGTON, DE — Incyte (Nasdaq: INCY) is set to present pivotal data from its hematology/oncology portfolio at the 2025 European Hematology Association (EHA) Congress, scheduled for June 12–15 in Milan. This includes a late-breaking oral presentation on its groundbreaking monoclonal antibody, INCA033989, aimed at treating essential thrombocythemia (ET).
“We’re looking forward to presenting new data from across our hematology/oncology portfolio at the 2025 EHA Congress, including late-breaking data for our first in class, mutCALR-directed monoclonal antibody, INCA033989,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development at Incyte. “We believe the data that will be presented at the late-breaking session demonstrate the impact of the novel mechanism of action of this monoclonal antibody against mutCALR-driven essential thrombocythemia (ET), and support its potential to be a disease-modifying agent and thus transform the treatment of patients with myeloproliferative neoplasms (MPNs) like essential thrombocythemia.”
Key Presentations
- INCA033989 Late-Breaking Oral Presentation:
INCA033989, a first-in-class anti-mutant calreticulin antibody, aims to improve safety and efficacy for patients battling ET. The session takes place on Sunday, June 15, from 3:15–4:45 a.m. EDT (9:15–10:45 a.m. CEST). - Explore Cutting-Edge Treatments:
Presentations will also highlight INCA035784, Ruxolitinib, and Tafasitamab, offering new insights into treatments for myeloproliferative neoplasms and follicular lymphoma. - Poster Sessions Deep-Dive:
Findings on Axatilimab and INCB057643 (BET inhibitor) reveal advancements in chronic graft-versus-host disease and insights into myeloid disease management.
Impact and Future Prospects
The EHA presentations underscore the breadth of Incyte’s pipeline, which seeks to address challenges in diseases like myeloproliferative neoplasms (MPNs), myelofibrosis, and hematologic malignancies. Notably, INCA033989 has shown the potential to not just manage ET but to modify the course of the disease, marking a significant milestone in treatment development.
Alongside the conference, the company will host an in-person analyst and investor event on June 15 to discuss the implications of the mutCALR research.
Industry-Defining Data
By sharing its latest findings at EHA 2025, including advances in BET inhibitors and combination therapies, Incyte aims to redefine treatment standards across multiple hematology and oncology disorders. Through cutting-edge research and innovation, the company sets out to empower patients and clinicians with advanced, targeted therapies for complex conditions.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.